ATE486285T1 - Verfahren zur früherkennung von krebs - Google Patents

Verfahren zur früherkennung von krebs

Info

Publication number
ATE486285T1
ATE486285T1 AT07706065T AT07706065T ATE486285T1 AT E486285 T1 ATE486285 T1 AT E486285T1 AT 07706065 T AT07706065 T AT 07706065T AT 07706065 T AT07706065 T AT 07706065T AT E486285 T1 ATE486285 T1 AT E486285T1
Authority
AT
Austria
Prior art keywords
cancer
determining
kits
subject
methods
Prior art date
Application number
AT07706065T
Other languages
English (en)
Inventor
Nadir Arber
Original Assignee
Medical Res Fund Of Tel Aviv S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Fund Of Tel Aviv S filed Critical Medical Res Fund Of Tel Aviv S
Application granted granted Critical
Publication of ATE486285T1 publication Critical patent/ATE486285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07706065T 2006-01-31 2007-01-31 Verfahren zur früherkennung von krebs ATE486285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
ATE486285T1 true ATE486285T1 (de) 2010-11-15

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07706065T ATE486285T1 (de) 2006-01-31 2007-01-31 Verfahren zur früherkennung von krebs

Country Status (12)

Country Link
US (1) US9394569B2 (de)
EP (1) EP1994410B1 (de)
JP (1) JP5091163B2 (de)
AT (1) ATE486285T1 (de)
DE (1) DE602007010108D1 (de)
DK (1) DK1994410T3 (de)
ES (1) ES2355388T3 (de)
IL (1) IL193097A (de)
PL (1) PL1994410T3 (de)
PT (1) PT1994410E (de)
SI (1) SI1994410T1 (de)
WO (1) WO2007088537A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1994410E (pt) 2006-01-31 2011-01-10 Medical Res Fund Of Tel Aviv Sourasky Medical Ct Métodos e estojos para detecção precoce de cancro ou de predisposição a este
US9034587B2 (en) 2007-12-10 2015-05-19 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing cancer
BRPI0919882A8 (pt) * 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
EP2542696B1 (de) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Theranostik-biomarker
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
ES2656967T3 (es) 2010-05-21 2018-03-01 The Governors Of The University Of Alberta Métodos para la evaluación de cáncer colorrectal y pólipos colorrectales mediante medición de metabolitos en orina
EP3052651B1 (de) * 2013-10-01 2019-11-27 Life Technologies Corporation Systeme und verfahren zum nachweis von strukturvarianten
US11714089B2 (en) 2017-05-21 2023-08-01 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Combination of markers for diagnosing cancer
EP3447154A1 (de) * 2017-08-23 2019-02-27 Instytut Genetyki Sadowej Jolanta Powierska - Czarny Verfahren zur detektion von mutationen, polymorphismen und spezifischen dna-sequenzen auf dna-matrizen mit dna-bildgebungstechniken zur verwendung in der medizinischen diagnostik und forensischen genetik
EP3759493A1 (de) * 2018-02-28 2021-01-06 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Verfahren zur diagnose und behandlung von blasenkrebs
EP3888021B1 (de) 2018-11-30 2024-02-21 Caris MPI, Inc. Molekulare profilierung der nächsten generation
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
CA3163319A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571539A4 (en) * 1991-02-05 1994-06-29 Kamal Bahar Simple test for detecting carcinoembryonic antigen
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
US6974672B2 (en) * 2002-03-19 2005-12-13 Amgen Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
US20090011407A1 (en) * 2003-11-26 2009-01-08 The Ohio State University Research Foundation Polymorphic Cd24 Genotypes that are Predictive of Multiple Sclerosis Risk and Progression
CA2453198A1 (en) * 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
AU2005217375C1 (en) * 2004-02-19 2012-06-07 Yale University Identification of cancer protein biomarkers using proteomic techniques
PT1994410E (pt) 2006-01-31 2011-01-10 Medical Res Fund Of Tel Aviv Sourasky Medical Ct Métodos e estojos para detecção precoce de cancro ou de predisposição a este

Also Published As

Publication number Publication date
IL193097A0 (en) 2009-02-11
DE602007010108D1 (de) 2010-12-09
JP2009525041A (ja) 2009-07-09
WO2007088537A2 (en) 2007-08-09
ES2355388T3 (es) 2011-03-25
EP1994410B1 (de) 2010-10-27
SI1994410T1 (sl) 2011-03-31
DK1994410T3 (da) 2011-01-31
EP1994410A2 (de) 2008-11-26
JP5091163B2 (ja) 2012-12-05
PL1994410T3 (pl) 2011-12-30
PT1994410E (pt) 2011-01-10
US9394569B2 (en) 2016-07-19
WO2007088537A3 (en) 2007-10-25
US20100062450A1 (en) 2010-03-11
IL193097A (en) 2013-03-24

Similar Documents

Publication Publication Date Title
ATE486285T1 (de) Verfahren zur früherkennung von krebs
WO2010005991A3 (en) Circulating tumor and tumor stem cell detection using genomic specific probes
BRPI0607508B8 (pt) método para detecção e/ou classificação de distúrbios proliferativos celulares colorretais ou hepatocelulares, e uso do mesmo
WO2013022995A3 (en) Biomarker compositions and methods
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
ATE522627T1 (de) Verfahren zur herstellung von nukleinsäuresonden
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
WO2013134786A3 (en) Biomarker compositions and methods
RU2013146242A (ru) Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов
MX2010010465A (es) Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ.
TW200643175A (en) Markers for prenatal diagnosis and monitoring
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
ATE488604T1 (de) System zum nachweis von polynukleotiden
EA200970695A1 (ru) Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации
WO2008140463A3 (en) Biomarker panels for assessing radiation injury and exposure
WO2004030511A3 (en) Prostate cancer biomarkers
EP2212700B8 (de) Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE429495T1 (de) Nukleinsäuren für die apoptose von krebszellen
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
EP2029745A4 (de) Diagnoseverfahren und -marker
ATE555214T1 (de) Verfahren zur diagnose proliferativer erkrankungen durch detektion von genmethylierung
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
WO2010020619A3 (en) Susceptibility to dasatinib

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1994410

Country of ref document: EP